Advertisement

Clinical Trials of Recombinant Factor VIII

  • Gilbert C. WhiteII
  • Campbell W. McMillan
  • Edward D. Gomperts
  • Joseph E. AddiegoJr.
  • Hans H. Brackmann
  • Doreen B. Brettler
  • Joan C. Gill
  • Jonathon C. Goldsmith
  • W. Keith Hoots
  • Craig M. Kessler
  • C. Thomas Kisker
  • Y. Laurian
  • B. Lewis
  • Jeanne M. Lusher
  • Piero M. Mannucci
  • Messimo Morfini
  • Inge Scharrer
  • Sam Schulman
  • Martin L. Lee
  • Suzanne G. Courter
  • Henry S. Kingdon
  • Harold R. Roberts

Abstract

Preparations of plasma coagulation factors have been mainstays in the treatment of hemorrhagic disorders since their introduction in the middle 19th century. One of the first recorded uses of blood products to correct the hemorrhagic tendency in a hemophiliac was by Lane in 18401. By the middle of the present century, the use of whole plasma2 or various fractions derived from plasma3 was accepted therapy in hemorrhagic disorders although the large volumes required and the lack of plasma availability limited the use of these materials to major bleeding episodes. The development in 1964 of cryoprecipitate4, a cold-precipitated plasma fraction enriched in factor VIII, was a significant advance for patients with hemophilia. Not only was this used in the treatment of hemophilia for the next twenty years, but it was to be the starting material for many of the factor VIII concentrates to follow. In 1968, glycine-precipitated preparations of human factor VIII were first introduced for clinical use5. This procedure was amenable to large scale production of factor VIII and therefore to commercial preparation of factor VIII concentrates. By the early 1970s, factor VIII prepared in this way had become the major method for treatment of patients with hemophilia.

Keywords

Factor VIII Club Foot Domain Repeat Recombinant Factor VIII Human Factor VIII 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lane S. Haemorrhagic diathesis. Successful transfusion of blood. Lancet 1840; 1: 185–188.CrossRefGoogle Scholar
  2. 2.
    Feissly R. Etudes sur l’hemophilie. Bull Mem Soc Mod Hop Paris 1923; 47: 1778.Google Scholar
  3. 3.
    McMillan CW, Diamond LK, Surgenor DM. Treatment of classic hemophilia: The use of fibrinogen rich in factor VIII for hemorrhage and for surgery. New Eng J Med 1961;265: 224–230, 277-283.CrossRefGoogle Scholar
  4. 4.
    Pool JG, Hershgold EJ, Pappenhagen MR. High potency antihaemophilic factor concentrate prepared from cryoglobulin. Nature 1964; 203: 312.PubMedCrossRefGoogle Scholar
  5. 5.
    Brinkhous KM, Shanbrom E, Roberts HR, Webster WP, Fekete R, Wagner RH. A new high-potency glycine precipitated antihemophilic factor (AHF) concentrate. J Am Med Assoc 1968; 205: 613–617.CrossRefGoogle Scholar
  6. 6.
    Horowitz B, Piet MPJ. Transmission of viral disease by plasma protein fractions. Plasma Ther Transfus Technol 1986; 7: 503–513.Google Scholar
  7. 7.
    Piszkiewicz D, Kingdon HS, Apfelzweig R, McDougal JS, Cort SP, Andrews J, Hope J, Cabridilla CD. Inactivation of HTLV-III/LAV during plasma fractionation. Lancet 1985; 2: 1188–1189.PubMedCrossRefGoogle Scholar
  8. 8.
    Prince AM, Horowitz B, Brotman B. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet 1896; 1: 706–710.Google Scholar
  9. 9.
    Schimpf K, Brackmann HH, Kreuz W, Kraus B, Haschke F, Schramm W, Moesseler J, Auerswald G, Sutor AH, Keohler K, Hellstern P, Muntean W, Scharrer I. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand’s disease with pasteurized factor VIII concentrate. New Eng J Med 1989; 321: 1148–1152.PubMedCrossRefGoogle Scholar
  10. 10.
    White GC II, McMillan CW, Kingdon HS, Shoemaker CB. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. New Eng J Med 1989; 320: 166–170.PubMedCrossRefGoogle Scholar
  11. 11.
    Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster B, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342–347.PubMedCrossRefGoogle Scholar
  12. 12.
    Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, Opperman H, Keck R, Wood Wl, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337–342.PubMedCrossRefGoogle Scholar
  13. 13.
    Truett MA, Blacher R, Burke RL, Caput D, Chu C, Dina D, Hartog K, Kuo CH, Masiarz FR, Merryweather JP, Najarian JR, Paschl C, Potter SJ, Pumma J, Quiroga M, Rail LB, Randolph A, Urdea M, Valenzuela P, Dahl HH, Favaloro J, Hansen J, Nordfang O, Ezban M. Characterization of the polypeptide composition of human factor VIII: C and the nucleotide sequence and expression of the human cDNA. DNA 1986; 4: 333–349.CrossRefGoogle Scholar
  14. 14.
    Ryden L Model of the active site in the blue oxidases based on the ceruloplasmin-plastocyanin homology. Proc Nat’l Acad Sci 1982; 79: 6767–6771.CrossRefGoogle Scholar
  15. 15.
    Fass DN, Hewick RM, Knutson GJ, Nesheim ME, Mann KG. Internal duplication and sequence homology in factors V and VIII. Proc Nat’l Acad Sci 1985; 82: 1688–1691.CrossRefGoogle Scholar
  16. 16.
    Kane WH, Davie EW. Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin. Proc Nat’l Acad Sci 1986; 83: 6800–6804.CrossRefGoogle Scholar
  17. 17.
    Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (95 kDa) of human factor VIII is dispensible for in vitro procoagulant activity. Proc Nat’l Acad Sci 1986; 83: 5939–5942.CrossRefGoogle Scholar
  18. 18.
    Eaton DL, Wood Wl, Eaton D, Hass PE, Hollingshead P, Wion K, Mather J, Lawn RM, Vehar GA, Gorman C. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry 1986; 25: 8343–8347.PubMedCrossRefGoogle Scholar
  19. 19.
    Pavirani A, Meulien P, Harrer H, Dott K, Mischler F, Wiesel M-L, Mazurier C, Cazenave J-P, Lecocq J-P. Two independent domains of factor VIII co-expressed using recombinant vaccinia viruses have procoagulant activity. Biochem Biophys Res Commun 1987; 145: 234–240.PubMedCrossRefGoogle Scholar
  20. 20.
    Burke RL, Pachl C, Quiroga M, Rosenberg S, Haigwood N, Nordfang O, Ezban M. The functional domains of coagulation factor VIII: C. J Biol Chem 1986; 261: 12574–12578.PubMedGoogle Scholar
  21. 21.
    Pittman DD, Marquette KA, Kaufman RJ. Expression and characterization of factor VIII and factor V hybrid molecules produced in mammalian cells. Thrombos Haemostas 1989; 62: 34 (abstract).Google Scholar
  22. 22.
    Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. An immunogenic region within residues Val1670-Glu1684of factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem 1988; 263: 5230–5234.PubMedGoogle Scholar
  23. 23.
    Bloom JW. The interaction of rDNA factor VIII, factor VIII des 979-1562 and factor VIII des 979-1562 derived peptides with phospholipid. Thrombos Res 1987; 48: 439–448.CrossRefGoogle Scholar
  24. 24.
    Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83: 1978–1984.PubMedCrossRefGoogle Scholar
  25. 25.
    Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Thrombos Haemostas 1989; 62: 34 (abstract).Google Scholar
  26. 26.
    Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352–6362.PubMedGoogle Scholar
  27. 27.
    van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor Villa in the activation of bovine factor X. J Biol Chem 1987; 256: 3433–3442.Google Scholar
  28. 28.
    Vehar GA, Davie EW. Preparation and properties of bovine factor VIII. Biochemistry 1980; 19: 401–416.PubMedCrossRefGoogle Scholar
  29. 29.
    Fulcher CA, Zimmerman TS. Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Nat’l Acad Sci 1982; 79: 1648–1652.CrossRefGoogle Scholar
  30. 30.
    Hoyer LW, Trabold NC. The effect of thrombin on human factor VIII. Cleavage of the factor VIII procoagulant protein during activation. J Lab Clin Med 1981; 97: 50–64.PubMedGoogle Scholar
  31. 31.
    Hultin MB, Jesty J. The activation and inactivation of human factor VIII by thrombin: Effect of inhibitors of thrombin. Blood 1981; 57: 476–482.PubMedGoogle Scholar
  32. 32.
    Pittman DD, Kaufman RJ. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Nat’l Acad Sci 1988; 85: 2429–2433.CrossRefGoogle Scholar
  33. 33.
    Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated protein C and its analogy with factor V. Blood 1984; 63: 486–489.PubMedGoogle Scholar
  34. 34.
    Kaufman RJ. High level expression of proteins in mammalian cells. In: Setlow JK ed. Genetic Engineering. Principles and Methods. Volume 9. New York: Plenum Press, 1987: 155–198.Google Scholar
  35. 35.
    Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 1989; ss9: 1233–1242.Google Scholar
  36. 36.
    White GC II, McMillan CW, Gomperts E, Addiego J Jr, Brackmann H, Brettler D, Gill J, Goldsmith J, Hoots K, Kessler C, Kisker T, Laurian Y, Lewis B, Lusher J, Mannucci P, Morfini M, Scharrer I, Schulman S, Lee M, Courter S, Kingdon H, Roberts H. Safety and efficacy of human factor VIII prepared by recombinant DNA techniques. Blood 1989: 74(Suppl.1): 55a.Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Gilbert C. WhiteII
  • Campbell W. McMillan
  • Edward D. Gomperts
  • Joseph E. AddiegoJr.
  • Hans H. Brackmann
  • Doreen B. Brettler
  • Joan C. Gill
  • Jonathon C. Goldsmith
  • W. Keith Hoots
  • Craig M. Kessler
  • C. Thomas Kisker
  • Y. Laurian
  • B. Lewis
  • Jeanne M. Lusher
  • Piero M. Mannucci
  • Messimo Morfini
  • Inge Scharrer
  • Sam Schulman
  • Martin L. Lee
  • Suzanne G. Courter
  • Henry S. Kingdon
  • Harold R. Roberts

There are no affiliations available

Personalised recommendations